Posted: 23 March 2023
Firebrick Pharma Limited is pleased to announce that its Phase 3 clinical trial of Nasodine Nasal Spray (Nasodine) as a treatment for the common cold has received the necessary ethics approvals to re-open for the 2023 common cold season.
Two clinical sites in Australia are now open for recruitment and three sites in South Africa will open in the next week This trial was 50% recruited in 2022 and then paused over the summer months, with the stated goal of re-opening in March 2023.
This target has been achieved. The primary endpoint population for the trial is 196 adult subjects with confirmed viral colds. The trial enrolled 100 subjects with confirmed viral colds in 2022, so the goal in 2023 is to enrol the remaining 96 subjects and then report trial results.
“Nasodine works by killing viruses, so establishing its performance in people with actual viral infections in a pivotal proof of efficacy,” said Firebrick Executive Chairman, Dr Peter Molloy.
“Typically, the common cold season starts in Autumn, so we expect to see recruitment escalate over the next several months and continue through the winter, with trial competition expected in July.”
